Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ondine Biomedical, Inc. (OBI) Price & Analysis

OBI Stock Chart & Stats

GBX 9.75GBX 0.00(0.00%)
At close: 4:00 PM EDT
GBX 10GBX 11GBX 12GBX 133 Aug17 Aug1 Sep14 Sep28 Sep20 Oct26 Oct
Day’s Range
GBX 9.50 - GBX 9.75
52-Week Range
GBX 7.50 - GBX 15.50
Previous Close
GBX 9.75
Volume
23.96K
Average Volume (3M)
253.14K
Market Cap
GBP 64.47M
Enterprise Value
GBP 77.17M
Total Cash (Recent Filing)
GBP 5.36M
Total Debt (Recent Filing)
GBP 278.87K
Price to Earnings (P/E)
―
Beta
0.30
Next Earnings
May 20, 2027
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The latest annual revenue increase indicates improving commercial traction and a growing base from which the company can develop its antimicrobial platform. If sustained, this expansion could provide greater operating scale and help support future investment in product development and commercialization.

Modest Leverage

Low debt relative to equity provides some balance-sheet flexibility and limits the immediate burden of interest and debt service. This gives the company more room to direct capital toward its photodynamic antimicrobial programs, although continued losses could still change its funding needs.

Defined Healthcare Application

A focused application in antimicrobial treatment and healthcare-associated infection prevention gives the company a clearly defined medical need to address. Concentrating on photodynamic technology may support specialization and product development around clinical infection-control use cases over time.

Bears Say

Severe Profitability Weakness

Extremely negative profitability and the sharp gross-margin decline show that revenue growth has not yet translated into a sustainable earnings model. Persistently weak margins can constrain reinvestment capacity, increase dependence on financing, and make future scaling less economically certain.

Worsening Cash Burn

Increasing operating and free-cash-flow outflows raise the company’s ongoing funding requirement while its commercial model is still developing. Unless revenue scales materially or spending is reduced, continued burn could require additional capital and dilute financial flexibility over the next several quarters.

Equity Volatility And Funding Reliance

Material changes in equity, including a prior period of negative equity, indicate that the capital structure can shift substantially as losses continue. This dependence on external funding may limit strategic flexibility and expose the company to financing pressure while profitability remains distant.

Ondine Biomedical, Inc. News

OBI FAQ

What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest share price was 7.50 p and its highest was 15.50 p in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is £64.47M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Sep 30, 2026. The company reported -0.016 p earnings per share for the quarter.
Is Ondine Biomedical, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 661,218,140 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -0.016 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in GB:OBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology